Prevail Therapeutics Inc. - common stock (PRVL): Price and Financial Metrics


Prevail Therapeutics Inc. - common stock (PRVL): $23.00

-0.02 (-0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRVL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRVL Stock Price Chart Interactive Chart >

Price chart for PRVL

PRVL Price/Volume Stats

Current price $23.00 52-week high $23.35
Prev. close $23.02 52-week low $9.02
Day low $22.97 Volume 2,619,900
Day high $23.13 Avg. volume 955,800
50-day MA $16.67 Dividend yield N/A
200-day MA $14.45 Market Cap 787.66M

Prevail Therapeutics Inc. - common stock (PRVL) Company Bio


Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.


PRVL Latest News Stream


Event/Time News Detail
Loading, please wait...

PRVL Latest Social Stream


Loading social stream, please wait...

View Full PRVL Social Stream

Latest PRVL News From Around the Web

Below are the latest news stories about Prevail Therapeutics Inc that investors may wish to consider to help them evaluate PRVL as an investment opportunity.

Lilly Completes Acquisition of Prevail Therapeutics

Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets.

Yahoo | January 22, 2021

INVESTOR ALERT: Monteverde & Associates PC Is Actively Investigating the Transaction

NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * ZAGG, Inc. (NASDAQ:ZAGG) relating to its proposed acquisition by Evercel, Inc and its group.

Yahoo | January 14, 2021

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates BPFH, SPWH, PRVL, SNCA; Shareholders Are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 13, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Boston Private Financial Holdings, Inc. (NASDAQ:BPFH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to SVB Financial Group.

Yahoo | January 13, 2021

SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

NEW YORK, NY / ACCESSWIRE / January 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * PNM Resources, Inc. (NYSE:PNM) relating to its proposed acquisition by Avangrid, Inc.

Yahoo | January 12, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates BPFH, MDCA, MTSC, PRVL; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to SVB Financial Group. Under the terms of the merger agreement, Boston Private shareholders will receive 0.0228 shares of SVB common stock and $2.10 of cash for each share of Boston Private they own. If you are a Boston Private shareholder, click here to learn more about your rights and options.MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Stagwell Med...

Yahoo | January 12, 2021

Read More 'PRVL' Stories Here

PRVL Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 0.00%
2020 45.74%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5121 seconds.